You can buy or sell Soligenix and other stocks, options, ETFs, and crypto commission-free!
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. Read More The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
Princeton, New Jersey
52 Week High
52 Week Low
PR NewswireApr 23
Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below. Dear Friends and Shareholders, I wanted to take this opportunity to provide an update, as well as to...
-$0.09 per share